ArticleReproductive sciences (Thousand Oaks, Calif.)2025
Investigation of the Efficacy of Umbilical Cord Mesenchymal Stem Cell and Melatonin Treatment in Premature Ovarian Failure Model.
Article in Reproductive sciences (Thousand Oaks, Calif.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Current Status of Animal Models for Premature Ovarian Insufficiency: Similarities to Clinical Manifestations and Therapeutic Applications.Tissue engineering and regenerative medicine · 2026Review
- From Genes to Lives: Integrating the Complexities of Primary Ovarian Insufficiency.International journal of molecular sciences · 2026Review
- An updated look into reactive oxygen species and cyclophosphamide-induced ovarian damage.Journal of ovarian research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Premature Ovarian Insufficiency (POI) may develop in young female patients due to chemotherapy treatments, which causes infertility. In addition to stem cell treatment, which is an effective method for POI in recent years, melatonin, which has high antioxidant properties, is also known to be effective. This study aimed to investigate the efficacy of melatonin, human umbilical cord-derived mesenchymal stem cell (hucMSC), and melatonin + human umbilical cord-derived mesenchymal stem cell (hucMSC) treatments on POI in cyclophosphamide-induced POI models in rats. Sixty female animals were included in the experiment and randomly divided into the control, cyclophosphamide, cyclophosphamide + melatonin, cyclophosphamide + hucMSC, and cyclophosphamide + hucMSC + melatonin groups. Except for the control group, the POI model was created by administering intraperitoneal cyclophosphamide to other groups. Afterward, half of the animals were euthanized to investigate the effectiveness of the treatment, and AMH, E2, FSH, LH values in the blood of the euthanized animals were investigated by ELISA method. Follicle count was conducted in ovarian tissues, and the rate of apoptosis was determined by caspase-3 immunostaining. Fertility test was conducted on the group without euthanasia, and the number of baby rats was compared. Post-treatment E2 and AMH values were at the highest level in the cyclophosphamide + hucMSC + melatonin group. FSH value was at the lowest level in the cyclophosphamide + hucMSC + melatonin group. No significant difference was found between the groups in terms of LH value. Recovery was achieved with treatment in all follicle development stages. Particularly, the number of secondary and Graff follicles was statistically significantly higher in the cyclophosphamide + hucMSC + melatonin group. In caspase-3 immunostaining, the highest level of apoptosis was observed in the cyclophosphamide group, while the highest level of recovery was seen in the cyclophosphamide + hucMSC + melatonin group. As a result of fertility, the highest number of babies was observed in the cyclophosphamide + hucMSC + melatonin group following POI treatment. This study revealed that the success rate of POI treatment increases not only with stem cell treatment but also with combined treatment. If stem cell treatments are combined with melatonin with strong antioxidant properties, not as mono-therapy, for the purpose of infertility treatment, the effectiveness of the treatment increases.
Indexed as
Identifiers
40813742What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.